trial updates for luspatercept in lr-mds: commands, medalist and elements-mds
Published 7 months ago • 120 plays • Length 2:14Download video MP4
Download video MP3
Similar videos
-
1:06
update on the commands trial: luspatercept is superior to esa-based therapy in lr-mds
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials
-
2:52
long-term evaluation of luspatercept in esa-intolerant/refractory lr-mds: medalist follow-up study
-
0:48
an introduction to the maxilus study: the optimal dose of luspatercept in lr-mds
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
1:25
the recent approval of imetelstat in lr-mds based on results of the imerge trial
-
13:39
key highlights in mds: treating lower-risk & higher-risk disease, trial updates, and more
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
1:34
personalizing treatment of transfusion-dependent anemia in lr-mds
-
2:08
hematological response to frontline treatment in lr-mds is associated with better os
-
4:21
evaluating luspatercept in combination with esas for the treatment of anemia in lr-mds
-
2:12
improving the treatment of low-risk mds: luspatercept, treatment sequencing & disease classification
-
3:24
results from the breselibet trial of brentuximab vedotin chemotherapy for r/r hodgkin lymphoma
-
1:01
recent and future changes in the landscape of aml: the addition of venetoclax and mrd eradication
-
1:00
findings from the commands study and the approval of luspatercept for lower-risk mds
-
2:21
unmet needs in lr-mds: rbc transfusion-dependence
-
2:30
medalist: luspatercept and erythropoiesis biomarkers in mds
-
0:56
the promise of luspatercept for the treatment of lower-risk mds
-
2:57
imetelstat for lr-mds: insights from the imerge trial